Foundation Medicine, Inc.
Formerly Foundation Genomics, Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2012 | $56 M | No. 3 | $50 to $250 million | equity | SEC | |
| Aug 2011 | $10 M | No. 2 | $10 to $50 million | equity | SEC | |
| Mar 2010 | $7 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Foundation Medicine, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2013).
SEC Form D · Jan 2013
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jan 2013
That is all the official record says: Foundation Medicine, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
7 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Google Ventures 2011, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Kleiner Perkins Caufield & Byers XIV, LLC | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| KPCB XIV Associates, LLC | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| KPCB XIV Founders Fund, LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Third Rock Ventures GP, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Third Rock Ventures LP | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| TRV GP, LLC | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 22 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jason W. Ryan | Executive officer | Jan 2013 |
| Kevin W. Krenitsky | Executive officer | Jan 2013 |
| Michael J. Pellini | Executive officer | Jan 2013 |
| Robert W. Hesslein | Executive officer | Jan 2013 |
| Kevin Krenitsky, M.D. | Executive officer | Aug 2011 |
| Michael Pellini, M.D. | Executive officer | Aug 2011 |
| Alexis Borisy | Alexis Borisy, M.S., President | Apr 2010 |
| Alexis W. Borisy | Director | Jan 2013 |
| Brook W. Byers | Director | Jan 2013 |
| David W. Schenkein | Director | Jan 2013 |
| Evan W. Jones | Director | Jan 2013 |
| Krishna W. Yeshwant | Director | Jan 2013 |
| Mark W. Levin | Director | Jan 2013 |
| Michael J. Pellini | Director | Jan 2013 |
| Alexis Borisy, M.S. | Director | Aug 2011 |
| David Schenkein | Director | Aug 2011 |
| Mark Levin | Director | Aug 2011 |
| Michael Pellini, M.D. | Director | Aug 2011 |
| Robert Tepper, M.D. | Director | Aug 2011 |
| Alexis Borisy | Alexis Borisy, M.S., President | Apr 2010 |
| Robert Tepper | Director | Apr 2010 |